Focus Partners Wealth
VNDA icon

Focus Partners Wealth’s Vanda Pharmaceuticals VNDA Stock Holding History

Focus Partners Wealth’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Buy
30,779
+16,650
+118% +$109K ﹤0.01% 2521
2026
Q1 		$97.6K Buy
+14,129
New +$109K ﹤0.01% 2516

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Wealth's VNDA Position: Q2 2026 in Review

Focus Partners Wealth increased its Vanda Pharmaceuticals (VNDA) stake by 118% in Q2 2026, buying an estimated $109K and bringing the position to 30,779 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #2521.

Focus Partners Wealth first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Focus Partners Wealth held 30,779 shares of Vanda Pharmaceuticals worth $188K as of Q2 2026.
  • Focus Partners Wealth bought 16,650 Vanda Pharmaceuticals shares in Q2 2026, an estimated $109K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2521 holding.
  • Focus Partners Wealth first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.